Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 47-58

  Ellis, Peter M ^a,b   Al Saleh, Khalid ^c  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Anti angiogenic agents; Fibroblast growth factor (FGF); Multitargeted kinase inhibitors; Non small cell lung cancer (NSCLC); Platelet derived growth factor (PDGF); Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; LINIFANIB; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BLEEDING; CANCER SURVIVAL; CHOLECYSTITIS; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TARGETING; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84866520947     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.02.004     Document Type: Review

References (90)

1. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003, 21:3016-3024.
2. Scagliotti G.V, Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26:3543-3551.
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 2002, 346:92-98.
4. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome [erratum appears in N Engl J Med. 2006 Oct 19;355(16)1746]. New England Journal of Medicine 2005, 353:133-144.
5. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009, 361:947-957.
6. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005, 353:123-132.
7. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
8. Reck M., von Pawel J., Zatloukal P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 2010, 21:1804-1809.
9. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006, 355:2542-2550.
10. Bonnesen B., Pappot H., Holmstav J., Skov B.G. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2009, 66:314-318.
11. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
12. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
13. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clinical Cancer Research 2008, 14:1407-1412.
14. Folkman J., Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987, 329:671-672.
15. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
16. Toi M., Matsumoto T., Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. The Lancet Oncology 2001, 2:667-673.
17. Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003, 9:669-676.
18. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clinic Proceedings 2006, 81:1241-1257.
19. Bergsten E., Uutela M., Li X., et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nature Cell Biology 2001, 3:512-516.
20. Wu E., Palmer N., Tian Z., et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008, 3:e3794.
21. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 2003, 111:1287-1295.
22. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB Journal 2004, 18:338-340.
23. Cabebe E., Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current Treatment Options in Oncology 2007, 8:15-27.
24. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & Growth Factor Reviews 2005, 16:159-178.
25. Rusnati M., Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Current Pharmaceutical Design 2007, 13:2025-2044.
26. Batchelor T.T., Sorensen A.G., Di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
27. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
28. Kano M.R., Morishita Y., Iwata C., et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. Journal of Cell Science 2005, 118:3759-3768.
29. Nissen L.J., Cao R., Hedlund E.-M., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. Journal of Clinical Investigation 2007, 117:2766-2777.
30. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clinical Cancer Research 2004, 10:415-427.
31. Wozniak A. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology 2011, 10.1016/j.critrevonc.2011.05.003.
32. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 2004, 22:2184-2191.
33. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of Clinical Oncology 2009, 27:1227-1234.
34. Sandler A.B., Schiller J.H., Gray R., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. Journal of Clinical Oncology 2009, 27:1405-1412.
35. Sandler A., Yi J., Dahlberg S., et al. Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2010, 5:1416-1423.
36. Ellis P.M., Blais N., Soulieres D., et al. A systematic review and canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Journal of Thoracic Oncology 2011, 6:1379-1391. doi:10.097/JTO.0b013e318220cb8e.
37. Leighl N., Reck M., de Haas S., et al. Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements 2009, 7:558.
38. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004, 22:3852-3859.
39. Burns T.F., Juergens R.A. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology 2010, 24:1223-1224.
40. Nadler E., Yu E., Ravelo A., Sing A., Forsyth M., Gruschkus S. Bevacizumab treatment to progression after chemotherapy: outcomes from a u.s Community practice network. The Oncologist 2011, 16:486-496.
41. NCCN Clinical practice guidelines in oncology™. Non Small Cell Lung Cancer. V.1.2011. Accessed Dec 10, 2010. Accessed at http://www.nccn.org/professionals/physician_gls/PDF.nscl.pdf.
42. Lu C., Kamat A.A., Lin Y.G., et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clinical Cancer Research 2007, 13:4209-4217.
43. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004, 64:7099-7109.
44. Blumenschein G.R., Gatzemeier U., Fossella F., et al. Phase II, Multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non small-cell lung cancer. Journal of Clinical Oncology 2009, 27:4274-4280.
45. Schiller J.H., Lee J.W., Hanna N.H., Traynor A.M., Carbone D.P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. Journal of Clinical Oncology 2008, 26:8014.
46. Schiller J.H., Flaherty K.T., Redlinger M., et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. Journal of Clinical Oncology 2006, 24:7194.
47. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:1835-1842.
48. Molina J.R., Dy G.K., Foster N.R., et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. Journal of Clinical Oncology 2011, 29. [Abstract 7513].
49. Cho B., Kim S., Heo D.S., et al. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2010, 28:7547.
50. Spigel D.R., Burris H.A., Greco F.A., et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:2582-2589.
51. Lind J.S.W, Dingemans A-MC, Groen H.J.M., et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical Cancer Research 2010, 16:3078-3087.
52. Gridelli C., Morgillo F., Favaretto A., et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of Oncology 2010, 21:417P.
53. Herbst R.S., Blumenschein G.R., Kim E.S., et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. ASCO Meeting Abstracts 2010, 28:7609.
54. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26:650-656.
55. Novello S., Scagliotti G.V., Rosell R., et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 2009, 101:1543-1548.
56. Reynolds C., Spira A.I., Gluck W.L., et al. Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients. Journal of Clinical Oncology 2011, 29. [Abstract 7549].
57. Socinski M.A, Scappaticci F.A., Samant M., Kolb M.M., Kozloff M.F. Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small cell lung cancer. Journal of Thorac Oncology 2010, 5:354-360.
58. Groen H.J.M., Socinski M., Grossi F., et al. Randomized phase ii study of sunitinib (SU) plus erlotinib (E) vs Placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC). Annals of Oncology 2010, 21:417P.
59. Scagliotti G.V., Krzakowski M., Szczesna A., et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic nonsmall cell lung cancer (NSCLC): a phase III study. Annals of Oncology 2010, 21:LBA6.
60. Nikolinakos P., Heymach J.V. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. Journal of Thoracic Oncology 2008, 3:131-134.
61. Laurie S.A., Gauthier I., Arnold A., et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology 2008, 26:1871-1878.
62. Goss G.D, Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. Journal of Clinical Oncology 2010, 28:49-55.
63. Dy G.K., Mandrekar S.J., Nelson G.D., et al. A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2010, 28:7603.
64. Gadgeel S.M., Wozniak A., Edelman M.J., et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2009, 27:e19007.
65. Choueiri T.K. Axitinib a novel anti-angiogenic drug with promising activity in various solid tumors. Current Opinion in Investigational Drugs 2008, 9:658-671.
66. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research 2006, 66:8715-8721.
67. Albert D.H., Tapang P., Magoc T.J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 2006, 5:995-1006.
68. Blumenschein G.R., Kabbinavar F., Menon H., et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:7528.
69. Scagliotti G., Vynnychenko I., Ichinose Y., et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2011, 29:LBA7512.
70. Tan E., Goss G.D., Salgia R., et al. A phase 2 trial of linifanib treatment in non-small cell lung cancer (NSCLC) patients. Annals of Oncology 2010, 21:416P.
71. Bahleda R., Felip E., Herbst R.S., et al. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. ASCO Meeting Abstracts 2008, 26:2564.
72. Bahleda R., Soria J., Harbison C., et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. ASCO Meeting Abstracts 2009, 27:8098.
73. O'Dwyer P.J., Papadopoulos K.P., Tolcher A.W., et al. MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience. ASCO Meeting Abstracts 2011, 29:3083.
74. Bhide R.S., Cai Z.-W., Zhang Y.-Z., et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. Journal of Medicinal Chemistry 2006, 49:2143-2146.
75. Cai Z.W., Zhang Y., Borzilleri R.M., et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2 1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). Journal of Medicinal Chemistry 2008, 51:1976-1980.
76. Ratain M.J., Schwartz G.K., Oza A.M., et al. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology 2011, 29. [Abstract 3079].
77. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 2002, 62:4645-4655.
78. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 2002, 62:7284-7290.
79. Aisner J., Manola J., Dakhil S.R., Stella P.J., Schiller J.H. Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-update on maintenance treatment, progression-free survival (PFS), and overall survival (OS). Journal of Clinical Oncology 2011, 29. [Abstract 7560].
80. De Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011, 29:1067-1074.
81. Herbst R.S, Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology 2010, 11:619-626.
82. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). Journal of Clinical Oncology 2010, 28. [Abstract 7525].
83. Natale R.B, Thongprasert S., Greco F.A., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:1059-1066.
84. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Research 2000, 60:4152-4160.
85. Laschke M.W., Elitzsch A., Vollmar B., Vajkoczy P., Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Human Reproduction 2006, 21:262-268.
86. Hilberg F., Roth G.J., Krssak M., et al. BIBF1120 triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research 2008, 68:4774-4782.
87. Reck M., Kaiser R., Eschbach C., et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Annals of Oncology 2011, 22:1374-1381.
88. Ellis P.M., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clinical Cancer Research 2010, 16:2881-2889.
89. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics 2007, 6:2012-2021.
90. Altorki N., Lane M.E., Bauer T., et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:3131-3137.